Group 1 - Soligenix is developing thermostabilized subunit vaccines, including SuVax™ and MarVax™, which have shown complete protection in non-human primate studies against filoviruses [2][10][27] - The company has received Orphan Drug Designation from the FDA for both Sudan ebolavirus and Marburg marburgvirus, providing market exclusivity and various financial benefits [5][13] - The thermostabilization technology allows vaccines to remain stable at ambient temperatures, facilitating easier distribution and use [2][20][27] Group 2 - The company is focused on rare diseases with unmet medical needs, with additional products in development for conditions like cutaneous T-cell lymphoma and inflammatory diseases [8][24] - Soligenix's vaccine programs are supported by government grants and contracts from agencies like NIAID and BARDA, enhancing its financial position [4][24] - The upcoming presentation at the ASM Microbe Conference will highlight the advantages of the company's vaccine technology compared to other platforms [10][11][26]

In addition to the positive clinical results to date, Soligenix has received regulatory validation with the granting of Orphan Drug Designation and Fast Track Status by the U.S. Food and Drug Administration (FDA), and Orphan Designation by the European Medicines Agency (EMA) for HyBryte™ in the treatment of early-stage CTCL. The full article can be found at: https://prismmarketview.com/prism-marketview-highlights-soligenixs- promising-hybryte-replication-trial-setting-the-stage-for-success/ NEW YORK, June 0 ...

Core Points - Soligenix, Inc. plans to implement a reverse stock split at a ratio of 1-for-16, effective June 5, 2024, with trading on a split-adjusted basis starting June 6, 2024 [1][3] - The reverse stock split was approved by stockholders, allowing the Board of Directors to determine the specific ratio within a range of 1-for-2 to 1-for-20 [2] - Following the split, the number of outstanding shares will decrease from approximately 15.8 million to about 987,490 shares, with adjustments made for fractional shares [4] Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing treatments for rare diseases with unmet medical needs [5] - The company is advancing its product HyBryte™ (SGX301) for cutaneous T-cell lymphoma and has completed a second Phase 3 study, seeking regulatory approvals for commercialization [5] - Other development programs include treatments for psoriasis, inflammatory diseases, and a ricin toxin vaccine candidate, supported by government funding [6]

Core Viewpoint - Soligenix, Inc. is urging eligible stockholders to vote their shares at the upcoming reconvened meeting on May 30, 2024, emphasizing the importance of shareholder participation in corporate governance [1][2]. Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs [5]. - The company is advancing its Specialized BioTherapeutics segment, which includes HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL), and is seeking regulatory approvals for potential worldwide commercialization [5]. - Other development programs include SGX302 for psoriasis, dusquetide (SGX942) for inflammatory diseases, and SGX945 for Behçet's Disease [5]. Public Health Solutions - The Public Health Solutions segment includes the development of RiVax®, a ricin toxin vaccine candidate, and vaccines targeting filoviruses and COVID-19 [6][7]. - The vaccine programs utilize the proprietary ThermoVax® technology and have received government funding from agencies such as NIAID, DTRA, and BARDA [7]. Voting Information - Eligible stockholders can vote by contacting the company's proxy solicitor, Alliance Advisors, and must have held shares as of the record date, April 10, 2024 [2]. - Stockholders who sold their shares after the record date are still encouraged to vote [2]. Proxy Materials - The company filed a definitive proxy statement and proxy card with the SEC on April 29, 2024, and stockholders are urged to read these documents for important information regarding the Annual Meeting [3][4].

Core Points - Soligenix, Inc. announced the adjournment of its 2024 Annual Meeting of Stockholders to solicit additional votes on proposals outlined in its definitive proxy statement [1][5] - The reconvened Annual Meeting is scheduled for May 30, 2024, at 9:00 a.m. Eastern Time, and will be held virtually [2] - As of the adjournment, approximately 48% of the shares of common stock had been voted, which was below the required quorum [3] Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing products for rare diseases with unmet medical needs [7] - The company is advancing HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma, and is seeking regulatory approvals following the successful completion of its second Phase 3 study [7] - Other development programs include SGX302 for psoriasis, dusquetide (SGX942) for inflammatory diseases, and SGX945 for Behçet's Disease [8] Public Health Solutions - The Public Health Solutions segment includes the development of RiVax®, a ricin toxin vaccine candidate, and vaccines targeting filoviruses and COVID-19 [9] - These programs are supported by government funding from agencies such as NIAID, DTRA, and BARDA [9]

Core Viewpoint - Soligenix, Inc. is urging its eligible stockholders to vote "FOR" a Reverse Stock Split to maintain its listing on The Nasdaq Capital Market, which is deemed crucial for attracting institutional support for its clinical programs [1][5]. Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs [5]. - The company is advancing its Specialized BioTherapeutics segment, particularly the HyBryte™ (SGX301) for cutaneous T-cell lymphoma, and is seeking regulatory approvals following the successful completion of its second Phase 3 study [5]. - Other development programs include SGX302 for psoriasis, dusquetide (SGX942) for inflammatory diseases, and SGX945 for Behçet's Disease [5]. Public Health Solutions - The Public Health Solutions segment includes the development of RiVax®, a ricin toxin vaccine, and vaccines targeting filoviruses and COVID-19 [6]. - This segment has received government funding from agencies such as NIAID, DTRA, and BARDA to support its vaccine programs [6]. Voting Information - Eligible stockholders can vote by contacting the company's proxy solicitor, and only those on record as of April 10, 2024, are eligible to participate [2]. - Stockholders who sold their shares after the record date are still encouraged to vote [2]. Proxy Materials - The company filed a definitive proxy statement and proxy card with the SEC on April 29, 2024, and stockholders are urged to read these documents for important information regarding the Annual Meeting [3][4].

NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an in-depth interview with Dr. Christopher Schaber, President and Chief Executive Officer of Soligenix, Inc. (NASDAQ:SNGX). The late-stage biopharmaceutical company is advancing a broad pipeline of therapeutic and vaccine candidates across its two business segments, emphasizing its strategic focus on diversified drug development. Soligenix has recently achieved success in its first Phase 3 clinical trial of HyBryte™ (synthetic hypericin) f ...

Under the Company's Public Health Solutions business segment, Soligenix is developing thermostabilized subunit vaccines. Thermostabilization is achieved by using a combination of Generally Recognized as Safe (GRAS) excipients and lyophilization (freeze-drying) to yield a single-vial presentation of vaccine that is stable at ambient and higher temperatures and that can be reconstituted with water for injection immediately prior to use. Mono-, bi- and tri-valent vaccine candidates for filoviruses (including S ...

For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc. This press release may contain forward-looking statements that reflect Soligenix's current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations, clinical trial enrollment, the expected timing for closing the offering described herein and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File No. 001-14778 SOLIGENIX, INC. (Exact name of registrant as specified in its charter) DELAWARE 41-1505029 ( ...